Trimethoprim and Triumeq

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this minor interaction is not currently available. Some minor drug interactions may not be clinically relevant in all patients. Minor drug interactions do not usually cause harm or require a change in therapy. However, your healthcare provider can determine if adjustments to your medications are needed.

In a study with 14 HIV-positive patients, coadministration of trimethoprim/sulfamethoxazole (TMP/SMX DS once a day for 5 days) and lamivudine (300 mg single dose on day 5) resulted in a mean decrease of 35% in lamivudine renal clearance and a mean increase of 43% in lamivudine area under the plasma concentration-time curve. The mechanism of interaction is thought to be competitive inhibition of tubular secretion by trimethoprim. Lamivudine did not affect the pharmacokinetic profile of TMP/SMX. Given the favorable safety profile of lamivudine, this interaction is unlikely to be of clinical significance. However, the effect of higher dosages of TMP/SMX on lamivudine pharmacokinetics has not been investigated.

Trimethoprim

Generic Name: trimethoprim

Brand name: Primsol, Trimpex, Proloprim

Synonyms: n.a.

What is Trimethoprim?

Triumeq

Generic Name: abacavir / dolutegravir / lamivudine

Brand name: Triumeq

Synonyms: n.a.

What is Triumeq?